OPKO Health, Inc. $OPK Holdings Decreased by Tejara Capital Ltd

Key Points

• Tejara Capital Ltd reduced its stake in OPKO Health by 29.8%, selling 365,306 shares, and now holds 860,344 shares valued at approximately $1.4 million.
• OPKO Health reported a quarterly EPS of (0.19), missing estimates, with revenue of $156.8 million, down 13.9% year-over-year.
• Recent analyst activity includes Wall Street Zen's downgrade of OPKO from "hold" to "sell" while LADENBURG THALM/SH SH upgraded it to "strong-buy."

Tejara Capital Ltd lessened its position in OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 29.8% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 860,344 shares of the biotechnology company's stock after selling 365,306 shares during the period. Tejara Capital Ltd owned approximately 0.11% of OPKO Health worth $1,428,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of OPK. Wells Fargo & Company MN grew its holdings in OPKO Health by 14.9% during the fourth quarter. Wells Fargo & Company MN now owns 229,262 shares of the biotechnology company's stock worth $337,000 after acquiring an additional 29,738 shares during the period. Raymond James Financial Inc. acquired a new position in shares of OPKO Health during the 4th quarter worth $221,000. Barclays PLC grew its stake in shares of OPKO Health by 68.7% during the 4th quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock worth $1,347,000 after purchasing an additional 373,032 shares during the period. XTX Topco Ltd grew its stake in shares of OPKO Health by 79.3% during the 4th quarter. XTX Topco Ltd now owns 194,804 shares of the biotechnology company's stock worth $286,000 after purchasing an additional 86,152 shares during the period. Finally, Zacks Investment Management acquired a new position in shares of OPKO Health during the 4th quarter worth $49,000. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Trading Up 2.2%

NASDAQ OPK traded up $0.03 during mid-day trading on Wednesday, reaching $1.39. 1,561,349 shares of the stock were exchanged, compared to its average volume of 2,806,725. OPKO Health, Inc. has a 1-year low of $1.11 and a 1-year high of $2.0350. The business's fifty day simple moving average is $1.33 and its 200 day simple moving average is $1.46. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41. The stock has a market capitalization of $1.10 billion, a PE ratio of -5.56 and a beta of 1.19.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $165.74 million. OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%.OPKO Health's revenue was down 13.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.01) earnings per share. On average, research analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

OPK has been the topic of several recent analyst reports. Wall Street Zen lowered shares of OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. Barrington Research restated an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a report on Thursday, May 1st. Zacks Research upgraded OPKO Health from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. JPMorgan Chase & Co. initiated coverage on OPKO Health in a report on Friday, April 25th. They issued a "neutral" rating on the stock. Finally, LADENBURG THALM/SH SH raised OPKO Health to a "strong-buy" rating in a report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $2.75.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost acquired 675,000 shares of OPKO Health stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $1.32 per share, for a total transaction of $891,000.00. Following the purchase, the chief executive officer directly owned 214,676,448 shares of the company's stock, valued at $283,372,911.36. The trade was a 0.32% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 49.69% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.